DGAP-News: Elanix Biotechnologies AG: Announces Subscription Price for New Shares in Capital Increase

Nachricht vom 10.11.2017 (www.4investors.de) -


DGAP-News: Elanix Biotechnologies AG / Key word(s): Capital Increase/Financing

Elanix Biotechnologies AG: Announces Subscription Price for New Shares in Capital Increase
10.11.2017 / 16:32


The issuer is solely responsible for the content of this announcement.
 

The information in this announcement is NOT for publication OR distribution in or into the United States of America, Australia, Canada or any jurisdiction in which such distribution or publication could be unlawful

PRESS RELEASE

Elanix Biotechnologies AG Announces Subscription Price for New Shares in Capital Increase

Berlin, November 10, 2017 -Elanix Biotechnologies AG ("Company"), a developer of tissue regeneration products and specialty cosmetics in dermatology and gynecology, today set the subscription price for the cash capital increase at EUR 3.75 per new share.

As announced in the Ad-hoc announcement of the same day, the company's shareholders, at the Annual General Meeting of 24 August 2017, resolved a cash capital increase by way of a rights offering to existing shareholders (indirect subscription rights). A total of up to 1,699,800 new shares will be offered for subscription to the shareholders at a ratio of 4:1 (four existing shares allow a subscription of 1 new share). Any new shares not subscribed will be offered to existing shareholders as supplemental subscriptions as well as to selected investors through a Private Placement. Expected proceeds from the offering will be used to fund corporate growth and further development of progenitor cell products.
The subscription period is expected to start on 23 November 2017, subject to approval of the prospectus by BaFin. The shares of Elanix Biotechnologies AG are expected to be traded with the attached subscription rights until 20 November 2017. Accordingly, shareholders who hold shares on that date will receive subscription rights. The subscription offer, as well as the prospectus once approved, will be published on the website of Elanix Biotechnologies AG at www.elanixbiotechnologies.com.

Elanix Biotechnologies AG develops and commercializes tissue regeneration products for wound care, dermatological and gynecological applications, and provides services in cell technologies. The company was founded in 2012 as a spin-out from the University Hospital of Lausanne (CHUV), Switzerland, to commercialize a patented human progenitor cell technology. Progenitor cells are fully differentiated yet immunologically neutral cells that are very potent inducers of tissue growth and healing. Elanix Biotechnologies owns GMP certified Master and Working human cell banks with vast quantities of cells.

Elanix Biotechnologies AG has its registered office in Berlin, Germany, with an office in Wiesbaden, Germany, and operational headquarters in Nyon, Switzerland. It is listed in the Regulated Market (General Standard) on the Frankfurt Stock Exchange under the ISIN DE000A0WMJQ4 (symbol ELN). Further information can be found at www.elanixbiotechnologies.com.

Press Contacts:

Elanix Biotechnologies
Halsin Partners
Tomas Svoboda, CEO
Mike Sinclair
Tel: +41 22 363 66 40
Tel: +44 (0)20 7318 2955
investor.relations@elanix-bt.com
msinclair@halsin.com

 

Forward-looking statements

This publication contains forward-looking statements subject to certain risks and uncertainties. Actual results may be materially different from those expressed or implied by such statements due to a variety of risk factors and uncertainties, such as changes in the business, economic and competitive situation, exchange rate fluctuations, uncertainties regarding litigation or investigation proceedings and the availability of financial resources. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. Elanix Biotechnologies AG disclaims any obligation to update these forward-looking statements.

Disclaimer
This publication may not be published, distributed or transmitted, directly or indirectly, in the United States of America (including its territories and possessions), Canada, Japan or Australia or any other jurisdiction where such an announcement could be unlawful. The distribution of this announcement may be restricted by law in certain jurisdictions and persons who are in possession of this document or other information referred to herein should inform themselves about and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.

This publication does not constitute an offer of securities for sale or a solicitation of an offer to purchase securities of Elanix Biotechnologies AG in the United States of America, Germany or any other jurisdiction. Nor does this disclosure constitute a prospectus within the meaning of EU Directive 2003/71/EC of the European Parliament and of the Council of November 4, 2003, as amended (the "Prospectus Directive"). Any public offering in Germany may only be made on the basis of a prospectus. Once approved by the Federal Financial Supervisory Authority (BaFin), the prospectus will be published on Elanix Biotechnologies AG's website. Any decision to invest in subscription rights or shares of Elanix Biotechnologies AG should be made solely on the basis of the prospectus.

Neither this announcement nor anything contained herein shall form the basis of, or be relied upon in connection with, any offer or commitment whatsoever in any jurisdiction. The securities referred to herein may not be offered or sold in the United States of America in the absence of registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the "Securities Act"). The securities of Elanix Biotechnologies AG have not been, and will not be, registered under the Securities Act.

This announcement does not constitute a recommendation concerning the placement of securities described in this announcement. Investors should consult a professional advisor as to the suitability of the Placement for the person concerned.

In the United Kingdom, this document is only directed at persons who (i) are investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended)(the "Order") or (ii) are persons falling within Article 49(2)(a) to (d) of the Order (high net worth companies, unincorporated associations, etc.) (all such persons together being referred to as "Relevant Persons"). This document must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this document relates is available only to Relevant Persons and will be engaged in only with Relevant Persons.

In member states of the European Economic Area which have implemented the Prospectus Directive (each, a "Relevant Member State"), this announcement and any offer, if made subsequently, is directed exclusively at persons who are "qualified investors" within the meaning of the Prospectus Directive. For these purposes, the expression "Prospectus Directive" means Directive 2003/71/EC (and amendments thereto, including the Directive 2010/73/EU), and includes any relevant implementing measure in the Relevant Member State.

No action has been taken that would permit an offering of the securities, a purchase of the securities or possession or distribution of this announcement in any jurisdiction where action for that purpose is required. Persons into whose possession this announcement comes are required to inform themselves about and to observe any such restrictions.












10.11.2017 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

Language:
English
Company:
Elanix Biotechnologies AG

Kurfürstendamm 32

10719 Berlin


Germany
ISIN:
DE000A0WMJQ4
WKN:
A0WMJQ
Listed:
Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf

 
End of News
DGAP News Service




628045  10.11.2017 





PfeilbuttonErgomed: „Evotecs fantastischer Erfolg ist ein positives Signal“ - Exklusiv-Interview
Pfeilbuttonmic AG: „Wir wollen Industrie 4.0 und Blockchain verbinden“ - Exklusiv-Interview
PfeilbuttonAURELIUS: „2017 wird das beste Jahr in unserer Unternehmensgeschichte” - Exklusiv-Interview


+++ Exklusive Interviews und Analysen - gratis in Ihre Mailbox! +++

Tragen Sie sich jetzt für unseren kostenlosen 4investors Newsletter ein.


Bestätigungslink nicht per Mail bekommen? Bitte kontrollieren Sie Ihren Spamordner!

Der 4investors Newsletter erscheint unregelmäßig, i.d.R. 2 bis 6 Mal pro Monat. Wir geben ihre Mailadresse an keinen Dritten weiter! Sie können den kostenlosen 4investors Newsletter jederzeit problemlos wieder abbestellen.
comments powered by Disqus


Aktuelle Nachrichten aus der 4investors-Redaktion

23.11.2017 - m-u-t AG hebt erneut die Gewinnprognose an
23.11.2017 - USU Software bestätigt Prognosen - „aktionärsfreundliche Dividendenpolitik”
23.11.2017 - Morphosys: Gute Neuigkeiten von Janssen!
23.11.2017 - KWS Saat bestätigt Prognose
23.11.2017 - JDC Group erwartet starkes viertes Quartal
23.11.2017 - Daldrup + Söhne: Neues zu Geothermieprojekten
23.11.2017 - Vita 34 meldet Gewinnrückgang - Prognose bestätigt
23.11.2017 - Evotec Aktie: Es bleibt sehr spannend!
23.11.2017 - First Sensor Aktie: Nächste Etappe der Rallye voraus?
23.11.2017 - Voltabox Aktie: Gelingt die Bodenbildung?


Chartanalysen

23.11.2017 - Evotec Aktie: Es bleibt sehr spannend!
23.11.2017 - First Sensor Aktie: Nächste Etappe der Rallye voraus?
23.11.2017 - Voltabox Aktie: Gelingt die Bodenbildung?
23.11.2017 - Nordex Aktie: Eine ganz heiße Sache
22.11.2017 - Geely Aktie: Haben sich die Bullen ausgetobt?
22.11.2017 - BYD Aktie: Aufwärtsdrang schon wieder beerdigt?
22.11.2017 - mic AG: Gelingt der Aktie jetzt der große Sprung?
22.11.2017 - Evotec Aktie: Jetzt einsteigen - oder draußen bleiben?
22.11.2017 - Medigene Aktie: Shortseller in der Falle?
21.11.2017 - Fintech Group: Achtung, Aktie mit einem weiteren Kaufsignal


Analystenschätzungen

23.11.2017 - ThyssenKrupp: Was ist mit Tata Steel?
23.11.2017 - ArcelorMittal: Gibt es wieder eine Dividende?
23.11.2017 - Fresenius: Sinnvolle Entscheidung
23.11.2017 - Software AG: IoT als Impulsgeber
23.11.2017 - SAF-Holland: USA bringt Impulse
23.11.2017 - Deutsche Telekom: Aktie bleibt ein Kauf
23.11.2017 - Vestas: Ein klares Minus für den Nordex-Konkurrenten
23.11.2017 - Drillisch: Ausgezeichnete Perspektiven
23.11.2017 - Salzgitter: Keine Kaufempfehlung mehr
23.11.2017 - Nordex Aktie: Beerdigt ein Analyst alle Hoffnungen?


Kolumnen

23.11.2017 - Bovespa konsolidiert im November 2017 nach kräftigem Kursanstieg - Commerzbank Kolumne
23.11.2017 - Wie kontrovers war die Diskussion im EZB-Rat wirklich? - National-Bank Kolumne
23.11.2017 - Deutschland - BIP: Exporte legen los – Außenbeitrag wichtiger Wachstumspfeiler - VP Bank Kolumne
23.11.2017 - BMW Aktie: Neue Tiefs möglich - UBS Kolumne
23.11.2017 - DAX: 13.000 Punkte wieder im Fokus - UBS Kolumne
22.11.2017 - US-Daten zum Auftragseingang im Fokus - National-Bank Kolumne
22.11.2017 - Beiersdorf Aktie: Neues Allzeithoch in Reichweite - UBS Kolumne
22.11.2017 - DAX: Verlorenes Terrain zurückerobert - UBS Kolumne
21.11.2017 - Politische Sondierungen in Berlin deuten in Summa auf Neuwahlen - National-Bank Kolumne
21.11.2017 - Jamaika gescheitert – was sind die Folgen für Kapitalmärkte und Wirtschaft - Commerzbank Kolumne

Werbung

All Right Reserved by minimalthemes - ©2014 Stoffels & Barck GbR